NCT01687426View on ClinicalTrials.gov

Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Glaucoma and Ocular Hypertension
Interventions
DRUG

Brimonidine Tartrate 0.025%

1 drop in each eye daily four times a day for 14 days

DRUG

Vehicle

1 drop in each eye daily four times a day for 14 days

Trial Locations (1)

01890

Clinical Site, Winchester

Sponsors

Lead Sponsor

Eye Therapies, LLC
All Listed Sponsors
lead

Eye Therapies, LLC

INDUSTRY

NCT01687426 - Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter